INTRODUCTION
Although simple oncoretroviral vectors have been extensively used to transduce hematopoietic stem cells (HSC) in preclinical models of gene therapy, recent clinical studies suggest that the standard transduction protocols used in conjunction with retroviral vectors generally do not lead to levels of gene transfer that are clinically relevant [1, 2] . One feature of most transduction protocols involving oncoretroviral vectors is the use of cytokine bprestimulation,Q a procedure designed to induce stem cell populations to proliferate, an essential requirement for oncoretroviral integration. Although preclinical studies in mice have shown that prestimulation does indeed improve the transduction of reconstituting stem cells, presumably because the majority of HSCs are quiescent upon removal from the bone marrow, such in vitro manipulations clearly induce the differentiation of HSCs and thereby lead to the loss of reconstitution activity [3, 4] . Effective gene transfer/reconstitution using protocols involving cytokine prestimulation would appear to necessitate finding a balance between achieving suitable levels of gene transfer and retaining acceptable levels of reconstituting activity. In the case of human cells, it may well be the inability to define effectively the experimental parameters that govern the relationship between these two important factors that accounts at least in part for the poor outcomes observed in the clinic.
Because lentiviruses are capable of infecting certain types of quiescent cells [5, 6] , there has been significant interest in the application of lentivirus-derived vectors to the transduction of HSCs, and indeed, a variety of investigators have defined protocols that lead to the efficient transduction of HSCs from different species, including human [7] [8] [9] [10] [11] [12] [13] . Interestingly, however, although proliferation per se does not appear to be necessary for efficient transduction of human HSCs, cytokine prestimulation does appear to improve gene transfer, likely because truly resting HSCs (in the G0 phase of the cell cycle) are relatively resistant even to lentiviral vector transduction, and cytokine prestimulation essentially serves to bactivateQ the cells to enter the G1 phase of the cell cycle, a stage at which transduction may be relatively more efficient [14] . Therefore, paradoxically, despite the success reported with the use of lentiviral vectors for transduction of HSCs, there are lingering questions regarding whether cytokine treatment of cells will prove to be essential for the achievement of high levels of gene transfer even with lentiviral vectors and therefore should be a component of lentiviral vector transduction protocols used in the clinic. Previous studies by Barrette and co-workers [15] have partially addressed this important issue by comparing the efficiency of transduction of murine HSCs afforded by standard oncoretroviral and lentiviral vectors under different conditions of transduction. Interestingly, they reported that under conditions of minimal in vitro manipulation (no added cytokines), neither lentiviral nor oncoretroviral vectors were capable of efficiently transducing murine HSCs, while under conditions of standard cytokine prestimulation, both vectors achieved a comparable level of transduction. Those studies have fueled the debate as to whether in fact lentiviral vectors would offer advantages over oncoretroviral vectors in the clinical gene therapy setting.
Here, we report studies aimed at further evaluating the relative abilities of oncoretroviral and lentiviral vectors to transduce highly purified murine hematopoietic stem cells. To enable the successful reconstitution of lethally irradiated recipients with small numbers of genetically modified cells, we sought to develop transduction conditions that do not compromise hematopoietic stem cell function yet permit efficient transduction. The results presented below indicate that lentiviral vectors are uniquely able to transduce efficiently highly purified reconstituting stem cell targets under conditions of minimal in vitro manipulation.
RESULTS

In Vivo Assessment of Stem Cell Transduction by Lentiviral Vectors under Conditions of Minimal Cytokine Stimulation and Optimization of Additional Experimental Parameters
We have previously reported the identification and isolation of a population of murine bone marrow cells highly enriched in hematopoietic reconstitution activity (termed side population or bSPQ cells), based on the capacity of the cells to exclude actively the vital dye Hoechst 33342 [16, 17] . Because it is possible to reconstitute lethally irradiated recipients fully with small numbers (500-200) of SP cells, we chose those cells as targets for our transduction studies. As a prelude to the evaluation of different transduction protocols, we first established the relative reconstitution activity of SP cells cultured in the presence of either SCF and TPO [12, 18] or the combination of SCF, IL-3, and IL-6 [15] , in the absence of exposure to virus, to study whether in vitro culture of SP cells under different conditions of cytokine prestimulation could compromise the reconstituting capacity of the cells. To quantify the engraftment potential of the cells manipulated in different ways, we employed a CD45.1/CD45.2 competitive repopulation assay involving the cotransplantation of genetically modified cells with a fixed number of unmanipulated congenic bone marrow cells [16] so that both the efficiency of transduction and the reconstitutive ability of the genetically modified cells could be independently determined. As shown in Fig. 1A , culture of SP cells overnight in SCF, IL-3, and IL-6 led to a significant reduction in their reconstitution ability relative to unmanipulated cells. In contrast, cells cultured solely in the presence of SCF and TPO maintained levels of reconstitution comparable to those observed with fresh, unmanipulated cells. Based on these results, we chose the culture of cells in the presence of SCF and TPO as an essential aspect of the transduction protocol.
As our expectation was that under conditions of minimal cytokine stimulation, lentiviral vector transduction would be more likely to result in efficient gene marking in vivo than retroviral vector transduction, we next examined a number of other potentially important experimental parameters of the transduction process using solely lentiviral vectors. In the first set of such experiments, we used a high lentiviral multiplicity of infection (m.o.i.) to transduce 100 CD45.1 SP cells that were transplanted together with 2 Â 10 5 CD45.2 competitor cells (Fig. 1B) . Transduction was performed in serum-free medium containing Polybrene, with or without minimal stimulation (SCF and TPO), for either 4 or 24 h at 378C (Fig. 1C) . We had previously observed that the use of Polybrene (5 Ag/ml) per se does not compromise HSC potential, even after a 24-h incubation time (data not shown). We followed levels of engraftment and gene transfer for 8 months post-bone marrow transplantation (post-BMT). Efficient gene transfer was dependent on the presence of the cytokines (Fig. 1C,  left) and was enhanced by extended incubation times (Fig. 1C, bottom) . Under optimal conditions (Fig. 1C , bottom left),~95% of donor-derived cells expressed GFP for the duration of the study.
To determine whether the absolute amount of virus used for transduction (e. To document that HSCs transduced under the above conditions retained their full differentiation potential after BMT, we analyzed peripheral blood from transplanted mice using specific markers to identify macrophages, granulocytes, B lymphocytes, T lymphocytes, and erythroblasts. As shown in irradiated mice. In an effort to reduce the possibility that analysis of reporter gene expression might not properly reflect gene transfer efficiencies, we compared the performances of a series of both vector types, which made use of different internal promoters (CMV, PGK, and EF1a) to drive expression of the reporter GFP (Fig. 4B ) (see Materials and Methods for details). As shown in Fig. 4C , while transduction with oncoretroviral vectors led, in some cases, to detectable levels of reporter gene expression, the proportion of cells expressing the reporter was dramatically lower than that achieved using lentiviral vectors ( P = 0.0001). These in vivo results contrast with the in vitro analysis of gene transduction presented in Fig.  4A . Interestingly, although all internal promoters used in the study presented in Fig. 4C were able to induce GFP expression efficiently, the CMV promoter showed the highest levels of mean fluorescence (data not shown).
To rule out completely that difficulties with oncoretroviral vector-mediated gene expression in vivo could have in part accounted for the poor apparent bgene transferQ observed, we sacrificed all transplanted mice and analyzed their marrow cells for chimerism, for the efficiency of transduction both in whole bone marrow and within the stem cell compartment (SP cells), and for proviral copy number. As shown in Fig. 5A , bone marrow from all mice showed levels of chimerism that correlated well with that seen in peripheral blood. Moreover, all marrow samples expressed GFP at the same level as peripheral blood. Analysis of the level of GFP expression specifically in SP cells isolated from mice transplanted with lentiviral vector-transduced cells demonstrated efficient gene vector-mediated gene expression in those cells as well (Fig. 5B) . In contrast, mice receiving SP cells transduced with oncoretrovirus showed low to undetectable levels of GFP expression within the HSC fraction of marrow.
We performed Southern blot analysis of bone marrow DNA derived from recipients transplanted with either lentiviral or retroviral vector-transduced cells, both using DNA cleaved either with restriction enzymes that recognized sequences within the viral LTRs (see Fig. 6 ) or with enzymes that recognized a unique sequence in the interior of the proviral genomes (data not shown). In all cases we detected limited numbers of integrants (data not shown). In the case of DNA derived from animals transplanted with lentiviral-transduced cells, the proviral copy number averaged 3 copies per genome. As observed through analysis of reporter gene expression, the efficiency of gene marking with oncoretroviral vectors was poor, yet in some cases detectable (see Fig. 6 ).
DISCUSSION
The studies reported here were motivated in large part by recent reports by Fischer and co-workers, which described the development of leukemia-like syndromes in severe combined immunodeficiency disease (SCID) patients transplanted with cells transduced by oncoretroviral vectors [19] [20] [21] [22] [23] . Those studies have appropriately led to dramatically increased concerns about the safety of retroviral (and lentiviral) vector-mediated gene therapy approaches for diseases affecting hematopoietic cells and established a firm rationale for the development of new safer approaches to their genetic modification. The development of leukemia in the specific SCID-g C patient population has also provoked keen interest in understanding whether the nature of the target cells used for transduction and/or the specific manipulations of them in vitro used to achieve gene transfer may have contributed to the oncogenic process. Unfortunately, to date, few of these issues have been adequately addressed.
Our studies were based on the notion that even in the absence of mechanistic information explaining the serious adverse events associated with the SCID-g C trial, it may be possible to develop bsaferQ protocols for transferring genes into hematopoietic cells. Specifically, we focused on the development of transduction protocols that would result in a reduction in the total number of proviral insertions bintroducedQ into a recipient after bone marrow transplantation, relative to standard transduction protocols currently in widespread use, and that would limit the range of biologically distinct cell types introduced in vivo via transplantation. While several elements of the protocol we have developed have been employed previously in different experimental contexts by others [12] , our studies addressed directly a very specific issue of practical import that had not been adequately addressed in the past: the relative utility of lentiviral and oncoretroviral vectors for transduction of hematopoietic stem cells under conditions under which stem cell function is not compromised. As indicated earlier, Barrette et al. [15] concluded from their studies that lentiviral vectors offer no significant advantages over oncoretroviral vectors for the transduction of hematopoietic stem cells, based on studies that compared transduction protocols that made use of either a standard cytokine cocktail or no cytokines at all. Notably, those studies did not evaluate the conditions of minimal cytokine stimulation that we have shown here to both preserve stem cell function and provide for the effective bactivationQ of stem cells that renders them susceptible to efficient transduction. Our results clearly show that there is a distinct advantage to the use of lentiviral vectors for the transduction of purified stem cells under conditions that preserve their biological properties. It is interesting and somewhat surprising that the in vitro analysis of transduction presented in Fig. 4A did not reveal the superiority of lentiviral vectors for the transduction of SP cells. It is possible that either the subpopulation of SP cells most capable of expansion in vitro is compromised in their capacity for in vivo repopulation or that the levels of reporter expression observed could in part reflect expression from unintegrated proviral copies.
While our studies suggest that bsomeQ addition of cytokines is indeed required for efficient transduction of purified stem cells, other recent reports have described lentiviral vector-based protocols for the transduction of enriched or purified stem cells that do not involve the addition of any cytokines [24, 25] . Our studies, in fact, do not really conflict with those reports other than in the demonstration under our specific transduction conditions (m.o.i., serum-free medium, etc.) that transduction can be bimprovedQ by minimal cytokine stimulation. Notably, in neither of the studies cited above were the effects of the transduction conditions on the reconstitution activity of the cells used for bone marrow transplantation assessed, an important issue for our studies.
As shown in Fig. 6 , the conditions we have utilized for transduction of purified cells led to highly efficient gene transfer, as reflected by the presence of multiple proviral copies per cell in some cases. While such a result would appear to be contrary to the goal of blimitingQ the total number of integrations, there will likely be a need to bweighQ the possible disadvantages of multiple proviral insertions per cell (e.g., safety issues) with the possible therapeutic importance of obtaining robust transgene expression through the introduction of multiple proviral copies. In fact, we have demonstrated that it is possible to reduce the number of proviral copies per cell when making use of the protocol we have developed by simply reducing the m.o.i. (data not shown). However, in the clinical setting, it may be practically difficult to achieve a blowQ average proviral copy number via variation of m.o.i., without compromising the befficacyQ of the therapy. For this reason, we believe that it may be most advantageous (and practical) to make use of high m.o.i.'s but to limit dramatically the total number of provirally bmarkedQ cells that are introduced into the recipient, as the protocol we have described here achieves.
Overall, our studies offer promise for the implementation of clinical protocols for gene therapies involving human hematopoietic cells that may have an improved safety profile and that may lead to improved gene marking in vivo. In addition to limiting the absolute number of cells carrying proviral integrations introduced into patients, the use of small numbers of highly purified cells may have additional advantages from the standpoint of safety, if, for example, the target cell for oncogenic conversion sometimes represents a progenitor cell (abnormal or normal) rather than a normal reconstituting stem cell or a cell that uniquely arises through specific in vitro manipulations associated with cytokine prestimulation and significant in vitro culture. Such targets could be bbiologicallyQ more susceptible to oncogenic events than relatively bunmanipulatedQ cells, due to their proliferative status and/or other unique biological properties. Furthermore, standard cytokine activation protocols may lead to the activation of a large number of chromosomal genes involved in the control of stem cell proliferation and thereby increase the accessibility of chromosomal sequences associated with those genes to proviral insertion. In addition to the potential bsafetyQ advantages of the type of transduction protocol we have described here, we speculate that the ability to preserve levels of reconstitution activity comparable to fresh, unmanipulated cells, as we have documented, may prove to be an extremely critical determinant of successful gene marking in vivo. Clearly, the evaluation of transduction protocols similar to those we have described herein in a clinical setting is warranted.
MATERIALS AND METHODS
Viral production. Generation of lentiviral vectors was accomplished by a five-plasmid transfection procedure. Briefly, 293T cells were transfected using TransIT 293 (Mirus, Madison, WI, USA) according to the manufacturer's instructions with the backbone HRST vector together with four expression vectors encoding the packaging proteins Gag-Pol, Rev, Tat, and the G protein of the vesicular stomatitis virus (VSV). HRST is a thirdgeneration lentiviral SIN nonreplicative vector derived from the original pHRV CMV-lacZ vector previously described [5] . The expression of GFP is driven by one of three different internal promoters, CMV, PGK, and EF1a. The gagpol helper plasmid has been codon optimized for efficient mammalian expression and modified to reduce severely the homology with the gag sequences present in the vector packaging signal. In addition, it makes the gagpol expression Rev independent. All of the expression helper plasmids contain only the coding sequences, with minimal 5V or 3V untranslated sequences and no introns. In addition, the backbone contains the woodchuck hepatitis virus posttranscriptional regulatory element [26] , seven synthetic scaffold-matrix attachment regions [27] , and the central polypurine tract to enhance levels of transcription and gene expression. Viral supernatants were collected starting 24 h after transfection, for four consecutive times every 12 h, pooled, and filtered through a 0.45-Am filter. Viral supernatants were then concentrated~100-fold by ultracentrifugation in a Beckman centrifuge, for 3 h at 15,000 rpm. Using these protocols titers of~5 Â 10 8 to 1 Â 10 9 / ml were achieved. For oncoretroviral vector production the same transfection protocol detailed above was used, except that three plasmids were cotransfected into 293 T cells, including an MPSV-derived viral vector and its corresponding gagpol and VSV-G envelope.
HSC purification and viral transduction. Purified HSC were obtained by isolating bone marrow SP cells using fluorescence-activated cell sorting after Hoechst staining as previously described [16] , with some modifications. Briefly, femurs and tibias from mice were homogenized and bone marrow cells were filtered through a 70-Am filter and washed in PBS containing 2% FCS and 0.5% sodium azide. Cells were then resuspended in HBSS containing 2% FCS, 10 mM Hepes buffer, and antibiotics (all from Gibco, Grand Island, NY, USA) and stained with 8.8 Ag/ml Hoechst 33342 (Molecular Probes, Eugene, OR, USA) at a cell concentration of 5 Â 10 6 /ml. After the cells were incubated for 90 min at 378C, they were washed once and further purified by using a gradient of Ficoll-Paque Plus (Amersham Biosciences AB, Uppsala, Sweden) to remove red blood cells. Purified marrow cells were then sorted using a MoFlo high-speed cell sorter (DakoCytomation, Fort Collins, CO, USA). Except when specified, cells were kept on ice during the entire procedure. Viral transduction of sorted HSC was performed using StemPro SFM-34 medium (Gibco). When indicated, 20 ng/ml IL-3, 50 ng/ml IL-6, and 50 or 10 ng/ml SCF and 100 ng/ml TPO were added to the medium containing 5 Ag/ml Polybrene. All cytokines were purchased from R&D Systems (Minneapolis, MN, USA). Transduction was performed in round bottom 96-well plates, using 20 Al reaction volume, for either 4 or 24 h at 378C. Cells were then resuspended in 100 Al for transplantation or incubated for 3 days for FACS analysis.
Bone marrow transplantation. All mice were purchased from The Jackson Laboratory and maintained in a specific-pathogen-free animal facility at Harvard Medical School. All experiments included at least four mice per group. CD45.2 recipient mice were lethally irradiated with two doses of 7 Gy, 3 h apart, 1 day before BMT and maintained with antibiotic-supplemented water for 15 days. Transduced SP cells from CD45.1 donors alone or, when indicated, mixed with 2 Â 10 5 CD45.2 unfractionated marrow cells were injected retro-orbitally into recipient mice under isoflurane anesthesia. Peripheral blood was obtained from the retro-orbital plexus every 4 weeks and stained using fluorescenceconjugated anti CD45.1-PE and CD45.2-biotin/streptavidin-APC antibodies (BD Biosciences Pharmingen, San Diego, CA, USA), to calculate levels of chimerism. Levels of gene transfer were measured directly by detection of GFP expression. Analysis of multilineage gene transfer was done by staining peripheral blood with biotin-conjugated antibodies against B220, CD3, Mac1, Gr1, and TER119 surface antigens (BD Biosciences Pharmingen). Cells were incubated with antibodies for 30 min on ice, washed once, and resuspended in PBS/1% BSA for analysis. Dead cells were excluded using propidium iodide stain. Samples were analyzed in a FACSCalibur machine (Becton-Dickinson) and data processed by FlowJo software (Tree Star, Ashland, OR, USA). For secondary bone marrow transplantations, marrow samples were collected from primary recipient mice 6 months after primary BMT and used to reconstitute lethally irradiated recipients as described above. Statistical analyses were performed using Student's t test. All animal procedures were approved by the Standing Committee on Animals of Harvard Medical School.
Southern blot analysis. Genomic DNA was extracted 6 months after BMT from tibias, femurs, hips, and sternum bones of transplanted animals. Southern blot analysis using standard methods was performed on DNA digested with AflII (New England Biolabs, Beverly, MA, USA), which cuts once in each of the two viral LTRs, to estimate the proviral copy number per genome, or with BamHI (New England Biolabs), which cuts only once within the provirus, to analyze different viral integrants.
